MedTrace Logo

REPEAT Study - Resistance to ErythroPoietin Effectiveness Algorithm Trial

NCT00319150 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2009-02-12

No results posted yet for this study

Summary

A strategy for optimizing erythropoietin therapy in patients with erythropoietin resistance. A multi-centered, open-label, randomized, controlled trial.

Conditions

  • Kidney Failure, Chronic
  • Drug Resistance

Interventions

DRUG

erythropoietin

Decrease dosage by 12.5% q 2 weeks according to an algorithm.

Sponsors & Collaborators

  • Ortho Biotech, Inc.

    collaborator INDUSTRY

  • Queen's University

    lead OTHER

Principal Investigators

  • Karen E Yeates, MD, FRCP(C), MPH · Queens University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-10-31
Primary Completion
2009-02-28
Completion
2009-02-28

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00319150 on ClinicalTrials.gov